Company Acarix AB Nasdaq Stockholm
Equities
Advanced Medical Equipment & Technology
End-of-day quote
Other stock markets
|
||
- SEK | - |
05-14 | Transcript : Acarix AB, Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Acarix AB Approves Board Elections | CI |
Business Summary
Sales per Business
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cardiovascular Diagnostic Method and Associated Equipment
100.0
%
| 6 | 100.0 % | 6 | 100.0 % | +7.20% |
Sales per region
SEK in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
58.4
%
| 2 | 31.2 % | 4 | 58.4 % | +100.27% |
Germany
35.7
%
| 3 | 57.2 % | 2 | 35.7 % | -32.99% |
Sweden
3.0
%
| 0 | 6.8 % | 0 | 3.0 % | -53.05% |
Other
2.4
%
| 0 | 0.2 % | 0 | 2.4 % | +1,577.78% |
Austria
0.5
%
| 0 | 2.6 % | 0 | 0.5 % | -79.22% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Founder | 60 | 31/12/06 | |
Director of Finance/CFO | 60 | 31/12/15 | |
Jennifer Matson
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/12/21 |
Chief Operating Officer | 50 | 31/12/21 | |
Tobias Fritz
CTO | Chief Tech/Sci/R&D Officer | 45 | 31/12/20 |
Public Communications Contact | 45 | 31/12/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 51 | 10/05/21 | |
Ulf Rosén
BRD | Director/Board Member | 64 | 31/12/13 |
Director/Board Member | 70 | 10/05/21 | |
Director/Board Member | 59 | 31/12/19 | |
Mikael Thoren
BRD | Director/Board Member | 60 | 31/12/22 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 737,188,816 | 649,218,759 ( 88.07 %) | 0 | 88.07 % |
Company contact information
Sector
Sales per region
1st Jan change | Capi. | |
---|---|---|
-12.09% | 19.25B | |
-38.27% | 2.96B | |
+22.02% | 1.96B | |
-0.62% | 1.69B | |
+33.51% | 1.27B | |
-16.17% | 982M | |
-22.01% | 913M | |
+5.38% | 801M | |
-24.02% | 630M |
- Stock Market
- Equities
- ACARIX Stock
- Stock
- Company Acarix AB